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Let’s Talk
Reports of FOXP2 mutations in individuals with speech
and language disorders were heralded as providing a key
to the development of human language. This may be the
case, but the rarity of pathogenic FOXP2 mutations indi-
cates that this gene is probably not the major factor
contributing to common speech and language impair-
ment. Even so, FOXP2 is a transcription factor, making
any of the genes it regulates candidates for involvement
in common forms of speech and language impairment.
In order to ﬁnd these genes, Vernes et al. used antibodies
to FOXP2 in chromatin-immunoprecipitation experi-
ments and then did shotgun sequencing of the resulting
DNA fragments. Although the range of genes pulled out
of this experiment is not made available, the authors did
pull out a compelling gene, CNTNAP2. This member of
the neurexin family had already been associated with
autism spectrum disorders, including, in one study, an
association with language delay. Vernes et al. provide
evidence that FOXP2 negatively regulates expression of
CNTNAP2, and they use family-based association studies
to support the role of this gene in language development.
This was not the ﬁrst attempt to use chromatin immuno-
precipitation to isolate targets of FOXP2, but this was the
ﬁrst time that CNTNAP2 was identiﬁed. Why is that?
Previous studies used the chromatin immunoprecipita-
tions to probe promoter-based microarrays. It turns out
that theCNTNAP2 fragment that binds to FOXP2 is located
in an intron, meaning that it is in an unexpected regula-
tory region.
Vernes et al. N. Engl. J. Med. 359, 2337–2345. 10.1056/
NEJMoa0802828.
You Do Need Your Calcium—Even If You’re
a Lysosome
Niemann-Pick disease is a lysosomal-storage disorder that
causes a progressive neurodegeneration for which there is
no treatment. The gene for the most common form of
this disease, NPC1, is known, but neither its function nor
the underlying pathogenic process of this disease is clear.
A broad range of lipids accumulates in the lysosomes of
NPC1 cells, but we don’t know which are key to the devel-
opment of the disorder. The work by Lloyd-Evans et al.Thteases out some of the initiating steps in NPC1. They
show that one of the primary factors initiating the patho-
genesis of NPC1 is sphingosine storage. This leads to
calcium depletion in the acidic compartment of cells,
where it would normally be involved in vesicle trafﬁcking
and fusion. Ultimately, these trafﬁcking defects prevent
glycosphingolipids, sphingomyelin, and cholesterol from
getting to the endoplasmic reticulum, so they accumulate
in the acidic compartments. Delineating the involvement
of calcium in NPC1 pathogenesis gave the authors the idea
of trying to modulate the process using thapsigargin or
curcumin to increase cytosolic calcium and hopefully
restore endocytic transport. These treatments normalized
sphingolipid trafﬁcking in cell culture and improved
some aspects of disease in NPC1 mice, including an
increase in life expectancy, further supporting the role of
calcium in the disease process and making it a potential
target for NPC1 therapies.
Lloyd-Evans et al. Nat. Med. 14, 1247–1255. 10.1038/
nm.1876.
Serotonin: Not Just for Moods Anymore
Inactivating mutations in LRP5 cause osteoporosis pseudo-
glioma, a rare syndrome characterized by decreased bone
formation. Osteoblasts express this gene, so it is a logical
assumption that studying LRP5 in osteoblasts can uncover
the pathway through which it controls bone formation.
Yadav et al. started to do just that, but they noticed that,
ex vivo, Lrp5-/- osteoblasts proliferated just as well as
wild-type cells, hinting that there might be more to this
regulation. Using an extensive set of transgenic mice,
they ﬁnd that Lrp5 activity in the gut, not in the bone, is
what regulates bone formation. Lrp5 does this by control-
ling expression of Tph1, the rate-limiting enzyme in sero-
tonin biosynthesis in the duodenum. Loss of Lrp5 activity
in the gut leads to increased Tph1 expression, a correspond-
ing increase in circulating-serotonin levels, and ultimately
a decrease in bone mass. The authors are able to manipu-
late the bone-loss phenotype in Lrp5-/- mice by reducing
circulating-serotonin levels either pharmacologically, by
using a drug that inhibits serotonin synthesis, or through
dietary means, by implementing a low-tryptophan diet.
The ability to manipulate the phenotype in these mice
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people might be possible via this pathway. This has impli-
cations for more than just the people with osteoporosis
pseudoglioma. It has previously been shown that common
variation in LRP5 is associated with osteoporosis in
a general population. Moreover, Yadav et al. also show
that knocking out Tph1 expression in the gut prevents
mice from developing ovariectomy-induced osteoporosis,
a model of postmenopausal osteoporosis.
Yadav et al. Cell 135, 825–827. 10.1016/j.cell.
2008.09.059.
When Two and Two Do Not Equal Four
As our ability to high-throughput genotype has increased,
there has been an explosion in the number of conﬁrmed
genes associated with a variety of complex traits. Despite
these huge advances, it is likely that we are still seeing
only the tip of the iceberg. Many questions remain about
the overall genetic architecture of these traits, such as the
number of genes involved and how they interact tomodify
phenotype. To get at these problems, Shao et al. used
chromosome-substitution strains in mice and rats to study
a wide range of blood, bone, and metabolic traits. In these
panels, a collection of strains is generated from two
original inbred strains. Each single chromosome in the
‘‘host’’ strain is replaced individually with the correspond-
ing chromosome from the ‘‘donor’’ strain, so that you have
a series of inbred animals that each differ by one chromo-
some. On average, eight chromosomes signiﬁcantly
affected each trait, conﬁrming that the traits are polygenic.
But one can’t simply add the effects of each chromosome
together to explain the phenotypic differences between
the two parental strains. In mice, for example, over half
of the 41 traits examined had additive differences that
were more than ﬁve times that seen between the parental4 The American Journal of Human Genetics 84, 3–4, January 9, 2009strains, indicating a striking level of epistasis. This argues
against the idea that we can simply add the effects of risk
genotypes together to predict outcome for complex
genetic traits.
Shao et al. PNAS 105, 19910–19914. 10.1073/pnas.
0810388105.
Noncoding RNA Recruits Histone-Modifying
Enzyme for Gene Regulation
Air is a large noncoding RNA that silences imprinted genes
in cis on mouse chromosome 17, although its mode of
action has not been clear. Nagano et al. show that, at least
at some genes, Air does this by recruiting histone-modi-
fying enzymes to the DNA to induce transcriptional repres-
sion. In mouse placenta, Air silences the paternal allele of
Slc22a3 in cis, although biallelic expression is observed
later in development. At times when the paternal allele is
silenced, Air RNA can be found associated with the
Slc22a3 promoter, but this diminishes by the time biallelic
Slc22a3 expression is observed. Air appears to recruit the
G9a histone methyltransferase to transcriptionally repress
Slc22a3 through histone H3 lysine 9 trimethylation of the
promoter. The signiﬁcance of this recruitment is observed
with embryos that lack G9a expression; in the placenta,
there is a shift towards biallelic expression of Slc22a3.
The recruitment of G9a clearly has signiﬁcance for regula-
tion of Slc22a3, but Air must have other tricks up its sleeve.
Although Air is also involved in the regulation of expres-
sion of Igf2r, a gene found in the same imprinted cluster
as Slc22a3, the same enrichment for Air and G9a are not
observed at the Igf2r promoter, so the regulation at this
gene must occur through a different process.
Nagano et al. Science 322, 1717–1720. 10.1126/
science.1163802.
